Nextcure, Inc. insider trading
Every open-market purchase and sale by Nextcure, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Nextcure, Inc.’s insiders pay?
From November 19, 2019 to October 27, 2026, 3 insiders reported 4 open-market purchases and 1 sale not made under a pre-set plan in Nextcure, Inc. Twelve months after each purchase was reported, the shares were −90.0% against the S&P 500 on average (median −90.0%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 20, 2019 into $3,817 by November 2, 2026, −13.0% a year. It held shares 18% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,391 (+5.4% a year), and held throughout $26,903 (+15.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Adar1 Capital Management, LLC | 10% owner | 3 | — | — | 0 | — | October 27, 2026 |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Other | 0 | — | — | 1 | — | August 12, 2026 |
| Sofinnova Venture Partners Ix, L.P. | 10% owner | 1 | −90.0% (1) | 0% | 0 | — | November 19, 2019 |